Cargando…

Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy

BACKGROUND: The clinical benefit of immune checkpoint blockade (ICB) therapy is often limited by the lack of pre-existing CD8(+) T cells infiltrating the tumor. In principle, CD8(+) T-cell infiltration could be promoted by therapeutic vaccination. However, this remains challenging given the paucity...

Descripción completa

Detalles Bibliográficos
Autores principales:	McAuliffe, James, Chan, Hok Fung, Noblecourt, Laurine, Ramirez-Valdez, Ramiro Andrei, Pereira-Almeida, Vinnycius, Zhou, Yaxuan, Pollock, Emily, Cappuccini, Federica, Redchenko, Irina, Hill, Adrian VS, Leung, Carol Sze Ki, Van den Eynde, Benoit J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420668/ https://www.ncbi.nlm.nih.gov/pubmed/34479921 http://dx.doi.org/10.1136/jitc-2021-003218

Ejemplares similares

5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy
por: Cappuccini, Federica, et al.
Publicado: (2017)

Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer
por: Cappuccini, Federica, et al.
Publicado: (2016)

Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy
por: Lu, Chia-Sing, et al.
Publicado: (2020)

Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression
por: Ramirez-Valdez, Ramiro A., et al.
Publicado: (2023)

MCT4 blockade increases the efficacy of immune checkpoint blockade
por: Babl, Nathalie, et al.
Publicado: (2023)

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
por: Schoenfeld, A.J., et al.
Publicado: (2019)

The expression of the cancer testis antigen MAGE A4: A favorable prognostic biomarker in salivary gland carcinomas related to low tumor grading
por: Vital, Domenic, et al.
Publicado: (2018)

Frequent MAGE Mutations in Human Melanoma
por: Caballero, Otavia L., et al.
Publicado: (2010)

Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8(+) T cells
por: Dwyer, Connor J., et al.
Publicado: (2020)

ODP571 Blockade of ErbB-2 Nuclear Function Induces the Interferon Signaling Pathway in Breast Cancer Models Resistant to Trastuzumab
por: Elizalde, Patricia V, et al.
Publicado: (2022)

Correction: Frequent MAGE Mutations in Human Melanoma
por: Caballero, Otavia L., et al.
Publicado: (2010)

SUN-LB056 The Pharmacological Blockade of the Splicing Factor SF3B1 Exerts Antitumor Actions in Different Endocrine-Related Cancers
por: Gahete, Manuel, et al.
Publicado: (2019)

Heterologous prime boost COVID 19 vaccination
por: Launay, O., et al.
Publicado: (2022)

Pathogenicity of the MAGE family
por: Li, Sanyan, et al.
Publicado: (2021)

Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite
por: Renga, Giorgia, et al.
Publicado: (2022)

Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy
por: Liu, Xia, et al.
Publicado: (2022)

In vivo enhancement of the MAGE-specific cellular immune response by a recombinant MAGE1-MAGE3-TBHSP70 tumor vaccine
por: Junwei, Wang, et al.
Publicado: (2016)

Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma
por: Frias, Alex, et al.
Publicado: (2023)

Erratum to: In vivo enhancement of the MAGE-specific cellular immune response by a recombinant MAGE1-MAGE3-TBHSP70 tumor vaccine
por: Junwei, Wang, et al.
Publicado: (2017)

Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors
por: Hao, Xingxing, et al.
Publicado: (2021)

Downregulation of phosphoserine phosphatase potentiates tumor immune environments to enhance immune checkpoint blockade therapy
por: Peng, Zhi-Peng, et al.
Publicado: (2023)

Gallic acid induces T-helper-1-like T(reg) cells and strengthens immune checkpoint blockade efficacy
por: Deng, Biaolong, et al.
Publicado: (2022)

Cancer-Associated Fibroblasts Suppress CD8(+) T-cell Infiltration and Confer Resistance to Immune-Checkpoint Blockade
por: Jenkins, Liam, et al.
Publicado: (2022)

Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment
por: Xu, Pengfei, et al.
Publicado: (2023)

Heterologous Prime-Boost Combinations Highlight the Crucial Role of Adjuvant in Priming the Immune System
por: Ciabattini, Annalisa, et al.
Publicado: (2018)

Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments
por: Moreno-Vicente, Julia, et al.
Publicado: (2022)

Single-Cell Analysis Reveals a CD4(+) T-cell Cluster That Correlates with PD-1 Blockade Efficacy
por: Kagamu, Hiroshi, et al.
Publicado: (2022)

TGFβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism
por: Canè, Stefania, et al.
Publicado: (2021)

Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion
por: D'Alise, Anna Morena, et al.
Publicado: (2021)

TYRO3 blockade enhances anti-PD-1 therapy response by modulating expression of CCN1 in tumor microenvironment
por: Park, Miso, et al.
Publicado: (2023)

Soft tissue extension increases the risk of local recurrence after curettage with adjuvants for giant-cell tumor of the long bones: A retrospective study of 93 patients
por: van der Heijden, L, et al.
Publicado: (2012)

Custom osteotomy guides for resection of a pelvic chondrosarcoma
por: Blakeney, William G, et al.
Publicado: (2014)

Giant Cell Tumor (GCT) of Capitate
por: Narayana Gowda, BS, et al.
Publicado: (2012)

Metastatic adenocarcinoma of Proximal Femur treated by Custom made Hip Prosthesis
por: Pal, Chandra Prakash, et al.
Publicado: (2012)

Surgery of non-spinal skeletal metastases in renal cell carcinoma
por: Ratasvuori, Maire, et al.
Publicado: (2016)

Osteochondroma Arising from the Thoracic Transverse Process
por: Wenyuan, Ding, et al.
Publicado: (2009)

Computer-assisted surgery in orthopedic oncology: Technique, indications, and a descriptive study of 130 cases
por: Gerbers, Jasper G, et al.
Publicado: (2014)

Alarm symptoms of soft-tissue and bone sarcoma in patients referred to a specialist center
por: Dyrop, Heidi B, et al.
Publicado: (2014)

Pelvic irradiation does not increase the risk of hip replacement in patients with gynecological cancer: A cohort study based on 8,507 patients
por: Dybvik, Eva, et al.
Publicado: (2014)

Comparison of allograft-prosthetic composite reconstruction and modular prosthetic replacement in proximal femur bone tumors: Functional assessment by gait analysis in 20 patients
por: Benedetti, Maria Grazia, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_3nn9avjv96rdmqr7hrel8nneed